Investigators at Navigant Consulting Target Managed Care (Budget impact analysis of ocriplasmin for the treatment of symptomatic vitreomacular adhesion in the USA)

By a News Reporter-Staff News Editor at Insurance Weekly News -- Fresh data on Managed Care are presented in a new report. According to news reporting originating from San Francisco, California, by VerticalNews correspondents, research stated, "Vitreomacular traction (VMT) treatment options include watchful waiting, vitrectomy and intravitreal ocriplasmin injection (Jetrea). This analysis used results from the recently completed OASIS randomized clinical trial to evaluate the 2-year budget impact of ocriplasmin injection availability for treatment of stage I or II VMT without epiretinal membrane formation in a modeled US health plan. ?VMT prevalence, treatment patterns and disease resolution rates were from literature, a US retinal-specialist survey and the OASIS trial."

Our news editors obtained a quote from the research from Navigant Consulting, "Medicare payment rates were applied and a national scenario analysis was conducted. With ocriplasmin available, vitrectomy use and complications-related costs decreased. Budget impact of ocriplasmin to the health plan was US$143,599 over 2 years or US$0.0060 per-member per-month."

According to the news editors, the research concluded: "Ocriplasmin was projected to be minimally cost-additive at US$0.0060 per-member per-month over 2 years."

For more information on this research see: Budget impact analysis of ocriplasmin for the treatment of symptomatic vitreomacular adhesion in the USA. Journal of Comparative Effectiveness Research, 2018;():.

The news editors report that additional information may be obtained by contacting T.M. Yu, Navigant Consulting Inc., 101 California Street, Suite 4100, San Francisco, CA 94111, United States. Additional authors for this research include P.U. Dugel, J.A. Haller, P.K. Kaiser and R.J Arnold.

The direct object identifier (DOI) for that additional information is: https://doi.org/10.2217/cer-2018-0057. This DOI is a link to an online electronic document that is either free or for purchase, and can be your direct source for a journal article and its citation.

(Our reports deliver fact-based news of research and discoveries from around the world.)